Plasma and Cerebrospinal fluid (CSF) Abeta42 for the differential diagnosis of Alzheimer's disease dementia in participants diagnosed with any dementia subtype in a specialist care setting

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 1, 2014, Pages

  Kokkinou, Michelle ^a   Smailagic, Nadja ^b   Noel Storr, Anna H ^c   Hyde, Chris ^d   Ukoumunne, Obioha ^d   Worrall, Rosie E ^c   Hayen, Anja ^c   Desai, Meera ^c   Ritchie, Craig ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITY OF EXETER MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER;

ALZHEIMER DISEASE; ARTICLE; CLINICAL PROTOCOL; DEMENTIA; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; DSM-III-R; DSM-IV; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; ICD-10; INTERMETHOD COMPARISON; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; STANDARD; SYSTEMATIC REVIEW;

EID: 84970010380     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD010945     Document Type: Article

References (48)

1. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al.The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendation from the National Institute on Ageing and Alzheimer's Association workgroup. Alzheimer's & Dementia 2011;7(3):270-9.
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3rd revised edition. American Psychiatric Association 1987.
3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th edition. American Psychiatric Association 1994.
4. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th edition (revised). American Psychiatric Association, Washington, DC 2000.
5. Boxer AL, Miller BL. Clinical features of frontotemporal dementia. Alzheimer Disease & Associated Disorders 2005;19:S3-6.
6. Burns A, O'Brien J, Ames D. Dementia. Oxford University Press 2005.
7. Chui HC, Victoroff JI, Margolin D, Jagust W, Shankle R, Katzman R. Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer's Disease Diagnostic and Treatment Centers. Neurology 1992;42(3 pt 1):473-80.
8. Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, Barberger-Gateau P, et al.Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurolology 2010;9(11):1119-27.
9. Fagan TI. Nomogram for Bayes' theorem. New England Journal of Medicine 1975;293:257.
10. Fagan A, Mintun M, Mach R, Lee S-Y, Dence C, Shah A, et al.Inverse relation between in vivo amyloid imaging load and CSF Aβ42 in humans. Annals of Neurology 2006;59(3):512-19.
11. Glanville JM, Cikalo M, Crawford F, Dozier M, McIntosh H. Handsearching did not yield additional unique FDG-PET diagnostic test accuracy studies compared with electronic searches: a preliminary investigation. Research Synthesis Methods 2012;3(3):202-13.
12. Greenhalgh T, Peacock R. Effectiveness and efficiency of search methods in systematic reviews of complex evidence: audit of primary sources. BMJ 2005;331:1064-5.
13. Kapaki E, Liappas I, Paraskevas GP, Theotoka I, Rabavilas A. The diagnostic value of tau protein, beta -amyloid (1-42) and their ratio for the discrimination of alcohol-related cognitive disorders from alzheimer's disease in the early stages. International Journal of Geriatric Psychiatry 2005;20(8):722-9.
14. Kapaki EN, Paraskevas GP, Tzerakis NG, Sfagos C, Seretis A, Kararizou E, et al.Cerebrospinal fluid tau, phospho-tau181 and b-amyloid1-42 in idiopathic normal pressure hydrocephalus: a discrimination from Alzheimer's disease. European Journal of Neurology 2007;14(2):168-73.
15. Knapp M, Prince M. Dementia UK. Dementia UK 2007; Vol. Available from: http://alzheimers.org.uk/site/scripts/download_info.php/fileID=2.
16. Kril JJ, Halliday GM. Brain shrinkage in alcoholics: a decade on and what have we learned?. Progress in Neurobiology 1999;58(4):381-7.
17. Le Bastard N, Aerts L, Leurs J, Blomme W, De Deyn PP, Engelborghs S. No correlation between time-linked plasma and CSF Abeta levels. Neurochemistry International 2009;55(8):820-5.
18. Leeflang MM, Scholten RJ, Rutjes AW, Reitsma JB, Bossuyt PM. Use of methodological search filters to identify diagnostic accuracy studies can lead to the omission of relevant studies. Journal of Clinical Epidemiology 2006;59(3):234-40.
19. Lopes MA, Furtado EF, Ferrioli E, Litvoc J, Bottino CM. Prevalence of alcohol-related problems in an elderly population and their association with cognitive impairment and dementia. Alcoholism: Clinical and Experimental Research 2010;34(4):726-33.
20. Lunn DJ, Thomas A, Best N, Spiegelhalter D. WinBUGS - a Bayesian modelling framework: concepts, structure, and extensibility. Statistics and Computing 2000;10:325-37.
21. Macaskill P, Gatsonis C, Deeks JJ, Harbord RM, Takwoingi Y. Chapter 10: Analysing and Presenting Results. In: Deeks JJ, Bossuyt PM, Gatsonis C (editors), Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy Version 1.0. The Cochrane Collaboration, 2010. Available from: http://srdta.cochrane.org/.
22. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, et al.Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996;47(5):1113-24.
23. McKeith IG. Dementia with Lewy bodies. British Journal of Psychiatry 2002;180:144-7.
24. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, et al.Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005;65(12):1863-72.
25. McKhann GM, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34(7):939-44.
26. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Clifford RJ, Kawas CH, et al.The diagnosis of dementia due to Alzheimer's disease: recommendation from the National Institute on Ageing and Alzheimer's Association workgroup. Alzheimer's & Dementia 2011;7(3):263-9.
27. Moher D, Liberati A, Tetzlaff J, Altman DG, the PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Medicine 2009;6(7):e1000097.
28. Mollenhauer B, Bibl M, Wiltfang J, Steinacker P, Ciesielczyk B, Neubert K, et al.Total tau protein, phosphorylated tau (181p) protein, beta-amyloid(1-42), and beta-amyloid(1-40) in cerebrospinal fluid of patients with dementia with Lewy bodies. Clinical Chemistry and Laboratory Medicine 2006;44(2):192-5.
29. Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, et al.Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998;51:1546-54.
30. Otto M, Esselmann H, Schulz-Shaeffer W, Neumann M, Schröter A, Ratzka P, et al.Decreased ß-amyloid1-42 in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Neurology 2000;54(5):1099-102.
31. Parkkinen L, Pirttilä T, Alafuzoff I. Applicability of current staging/categorization of á-synuclein pathology and their clinical relevance. Acta Neuropathologica 2008;115(4):399-407.
32. Quinn TJ, McShane R, Fearon P, Young C, Noel-Storr A, Stott DJ. IQCODE for the diagnosis of Alzheimer's disease dementia and other dementias within a community setting. Cochrane Database of Systematic Reviews 2012, Issue 9. [DOI: 10.1002/14651858.CD010079]
33. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2013.
34. Riemenschneider M, Wagenpfeil S, Diehl J, Lautenschlager N, Theml T, Heldmann B, et al.Tau and Aß42 protein in CSF of patients with frontotemporal degeneration. Neurology 2002; Vol. 58, issue 11:1622-8.
35. Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, et al.Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993; Vol. 43, issue 2:250-60.
36. Shoji M, Matsubara E, Murakami T, et al.Cerebrospinal fluid tau in dementia disorders: a large scale multicenter study by a Japanese study group. Neurobiology of Aging 2002; Vol. 23, issue 3:363-70.
37. Spies PE, Melis RJ, Sjögren MJ, Rikkert MG, Verbeek MM. Cerebrospinal fluid alpha-synuclein does not discriminate between dementia disorders. Journal of Alzheimer's Disease 2009;16(2):363-9.
38. College Station. TX: StataCorp LP. Stata Statistical Software: Release 13. College Station. TX: StataCorp LP, 2013.
39. Sundelöf J, Giedraitis V, Irizarry MC, Sundström J, Ingelsson E, Rönnemaa E, et al.Plasma beta amyloid and the risk of Alzheimer disease and dementia in elderly men: a prospective, population-based cohort study. Archives of Neurology 2008; Vol. 65, issue 2:256-63.
40. The Lund Manchester Groups. Clinical and neuropathological criteria for frontotemporal dementia. Journal of Neurology, Neurosurgery, and Psychiatry 1994;57(4):416-8.
41. Thomas VS, Rockwood KJ. Alcohol abuse, cognitive impairment, and mortality among older people. Journal of the American Geriatrics Society 2001; Vol. 49, issue 4:415-20.
42. Van Everbroeck B, Green AJ, Pals P, Martin JJ, Cras P. Decreased levels of amyloid-beta 1-42 in cerebrospinal fluid of Creutzfeldt-Jakob Disease patients. Journal of Alzheimer's Disease 1999; Vol. 1, issue 6:419-24.
43. Van Oijen M, Hofman A, Soares HD, Koudstaal PJ, Monique MB. Plasma Aâ140 and Aâ142 and the risk of dementia: a prospective case-cohort study. Lancet Neurology 2007; Vol. 5, issue 8:655-60.
44. Wetterling T, Kanitz RD, Borgis KJ. Comparison of different diagnostic criteria for vascular dementia (ADDTC, DSM-IV, ICD-10, NINDS-AIREN). Stroke 1996;27(1):30-6.
45. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al.QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Annals of Internal Medicine 2011;155(8):529-36.
46. World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders. 1993.
47. World Health Organization. Global Surveillance, diagnosis, and Therapy of Human Transmissible spongiform Encephalopathies: Report of WHO consultation. Geneva, Switzerland 1998.
48. Zerr I, Kallenberg K, Summers DM, et al.Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease. Brain 2009;132:2659-2668.